Sanofi's Toujeo demonstrated better control of blood sugar in TAKE CONTROL trial
A new randomized clinical trial, TAKE CONTROL, demonstrated better control of blood sugar without increasing the risk of hypoglycemia in people with type 2 diabetes by using Toujeo with a simple dose titration regimen compared with patients whose dose adjustment was managed by their physician. Participants initiated basal insulin with Toujeo or switched to Toujeo from another basal insulin (including insulin glargine 100 Units/mL, insulin detemir and NPH), while maintaining any previously administer oral antidiabetic drugs. After 6 months, patients with type 2 diabetes who used patient-driven titration achieved improvement of HbA1c (LS mean difference 0.13%, p=0.0247) compared with those who followed physician-driven titration. The proportion of patients reaching the pre-defined blood glucose target without experiencing severe and/or confirmed hypoglycemia was 67.5% in the patient-driven titration group, compared with 58.4% in the group using physician-driven titration (RR 1.15 [1.02; 1.3], p=0.0187). Similar proportions of patients in both groups (6.4% vs. 6.3%), experienced at least one severe and/or confirmed (less than54 mg/dL) hypoglycemic event. Full results will be presented in 2018.